Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL.

Clin Endocrinol (Oxf). 2014 Oct;81(4):523-8. doi: 10.1111/cen.12369. Epub 2013 Dec 12.

PMID:
24256515
2.

Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.

Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, Andrić Z, Panidis D.

Hum Reprod. 2016 Jun;31(6):1347-53. doi: 10.1093/humrep/dew076. Epub 2016 Apr 12.

PMID:
27076501
3.

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL.

BMC Endocr Disord. 2015 Apr 2;15:14. doi: 10.1186/s12902-015-0005-6.

4.

Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.

Polyzos SA, Goulis DG, Kountouras J, Mintziori G, Chatzis P, Papadakis E, Katsikis I, Panidis D.

Hormones (Athens). 2014 Oct-Dec;13(4):519-31. doi: 10.14310/horm.2002.1493. Epub 2014 Nov 5.

5.

A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease.

Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL.

Clin Endocrinol (Oxf). 2014 Jun;80(6):843-9. doi: 10.1111/cen.12258. Epub 2013 Aug 26.

PMID:
23746214
6.

Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.

Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, Sloboda DM, Olynyk JK, Hart R.

J Gastroenterol Hepatol. 2016 May;31(5):980-7. doi: 10.1111/jgh.13241.

7.

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity.

Kahal H, Aburima A, Ungvari T, Rigby AS, Dawson AJ, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL.

Clin Endocrinol (Oxf). 2013 Aug;79(2):252-8. doi: 10.1111/cen.12137. Epub 2013 May 11.

PMID:
23278130
8.

Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.

Vassilatou E, Vassiliadi DA, Salambasis K, Lazaridou H, Koutsomitopoulos N, Kelekis N, Kassanos D, Hadjidakis D, Dimitriadis G.

Eur J Endocrinol. 2015 Dec;173(6):739-47. doi: 10.1530/EJE-15-0567. Epub 2015 Sep 4.

PMID:
26340970
9.

MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.

Macut D, Božić-Antić I, Bjekić-Macut J, Tziomalos K.

Eur J Endocrinol. 2017 Sep;177(3):R145-R158. doi: 10.1530/EJE-16-1063. Review.

PMID:
28694246
10.

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.

Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J.

Diabetes Obes Metab. 2018 Jan;20(1):215-218. doi: 10.1111/dom.13053. Epub 2017 Aug 11.

PMID:
28681988
11.

Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.

Petta S, Ciresi A, Bianco J, Geraci V, Boemi R, Galvano L, Magliozzo F, Merlino G, Craxì A, Giordano C.

PLoS One. 2017 Nov 21;12(11):e0186136. doi: 10.1371/journal.pone.0186136. eCollection 2017.

12.

Hepatic manifestations of women with polycystic ovary syndrome.

Chen MJ, Ho HN.

Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:119-128. doi: 10.1016/j.bpobgyn.2016.03.003. Epub 2016 Apr 6. Review.

PMID:
27107966
13.

Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome.

Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ.

J Clin Endocrinol Metab. 2006 May;91(5):1741-7. Epub 2006 Feb 21.

PMID:
16492691
14.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.

Tzotzas T, Karras SN, Katsiki N.

Curr Vasc Pharmacol. 2017;15(3):218-229. doi: 10.2174/1570161114666161221115324. Review.

PMID:
28003008
15.

An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.

Brzozowska MM, Ostapowicz G, Weltman MD.

J Gastroenterol Hepatol. 2009 Feb;24(2):243-7. doi: 10.1111/j.1440-1746.2008.05740.x.

PMID:
19215335
16.

In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls.

Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E.

Hormones (Athens). 2009 Jul-Sep;8(3):199-206.

17.

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.

Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K.

ScientificWorldJournal. 2012;2012:496453. doi: 10.1100/2012/496453. Epub 2012 Aug 13.

18.

Pigment epithelium-derived factor, insulin sensitivity, and adiposity in polycystic ovary syndrome: impact of exercise training.

Joham AE, Teede HJ, Hutchison SK, Stepto NK, Harrison CL, Strauss BJ, Paul E, Watt MJ.

Obesity (Silver Spring). 2012 Dec;20(12):2390-6. doi: 10.1038/oby.2012.135. Epub 2012 May 29.

19.

Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.

Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I.

Hum Reprod. 2010 Jan;25(1):212-20. doi: 10.1093/humrep/dep380. Epub 2009 Nov 3.

PMID:
19887498
20.

Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.

Kim JJ, Kim D, Yim JY, Kang JH, Han KH, Kim SM, Hwang KR, Ku SY, Suh CS, Kim SH, Choi YM.

Aliment Pharmacol Ther. 2017 Jun;45(11):1403-1412. doi: 10.1111/apt.14058. Epub 2017 Mar 30.

Supplemental Content

Support Center